

Chemistry Europe

European Chemical

Societies Publishing

Chemistry A European Journal



Accepted Article

Title: Total Synthesis of anti-MRSA active Diorcinols and Analogues

Authors: Gordon Jacob Boehlich, Nina Schützenmeister, Jessica de Vries, Olivia Geismar, Mirja Gudzuhn, Wolfgang R. Streit, and Sebastian G. Wicha

This manuscript has been accepted after peer review and appears as an Accepted Article online prior to editing, proofing, and formal publication of the final Version of Record (VoR). This work is currently citable by using the Digital Object Identifier (DOI) given below. The VoR will be published online in Early View as soon as possible and may be different to this Accepted Article as a result of editing. Readers should obtain the VoR from the journal website shown below when it is published to ensure accuracy of information. The authors are responsible for the content of this Accepted Article.

To be cited as: Chem. Eur. J. 10.1002/chem.202002442

Link to VoR: https://doi.org/10.1002/chem.202002442

WILEY-VCH

COMMUNICATION

WILEY-VCH

Total Synthesis of anti-MRSA active Diorcinols and Analogues

G. Jacob Boehlich,^[a] Jessica de Vries,^[a] Olivia Geismar,^[a] Mirja Gudzuhn,^[b] Wolfgang R. Streit,^[b] Sebastian G. Wicha,^[a] and Nina Schützenmeister^{*[a]}

Dedicated to Prof. Dr. Christian Griesinger on the occasion of his 60th birthday.

[a]	M. Sc. G. J. Boehlich, M. Sc. J. de Vries M., M. Sc. O. Geismar, Prof. Dr. S. G. Wicha, Prof. Dr. N. Schützenmeiste
	Fachbereich Chemie, Institut für Pharmazie, Universität Hamburg
	Bundesstraße 45, 20146 Hamburg, Germany
	E-mail: nina.schuetzenmeister@chemie.uni-hamburg.de
[b]	M. Sc. M. Gudzuhn, Prof. Dr. W. R. Streit
	Department of Microbiology and Biotechnology, Universität Hamburg

Ohnhorststrasse 18, 22609 Hamburg, Germany Supporting information for this article is given via a link at the end of the document.

Abstract: Diorcinols and related prenylated diaryl ethers were reported to exhibit activity against Methicillin-resistant clinical isolates of *Staphylococcus aureus* (MRSA). Within these lines, we report the first total synthesis of diorcinol D, I, J, the proposed structure of Verticilatin and recently isolated antibacterial diaryl ether using an efficient and highly divergent synthetic strategy. These total syntheses furnish the diaryl ether coupling as key step. The total synthesis led to the structural revision of the natural product Verticilatin, which has been isolated from a plant pathogenic fungus. Furthermore, these structures were tested in order to determine their antibacterial activities against different MRSA strains as well as further Grampositive and Gram-negative bacteria.

Introduction

In the recent decade, multiple diaryl ethers with antibacterial and antifungal properties have been isolated from various fungal sources which are usually derived from prenylation of diorcinol **1** (figure 1). Most but not all of these compounds were named diorcinols.^[1a·g]



Figure 1. Structures of selected diorcinols and related compounds.

The simplest diorcinols exhibit prenylation of the aromatic rings. Other diorcinol derivatives might be derived from these prenylated compounds and seem to be generated by oxidation of the prenyl side chain followed by hydrolysis, ring closure or rearrangement.^[1c,2] Also examples of dibenzofuranes which might be generated by dehydrogenation have been isolated. ^[1c,1e] We were interested in the synthesis of the compounds **2a-c**^[1a-c] and **3a**^[1d] due to their reported excellent antibacterial activities against MRSA.

The key synthetic steps are exemplified in the synthesis of **3a** (Scheme 2). Building block **6a** should be generated by prenylation of monomethyl orcinol **5** which is then supposed to be coupled in a diaryl ether coupling. The resulting diaryl ether **7a** may then be deprotected to generate the natural compound **2a**, or converted to **3a** in a biomimetic approach by oxidation and rearrangement.



Scheme 1. Key steps in the synthesis of diorcinols.

synthesis started with the monodemethylation The of commercially available dimethyl orcinol 8 which has to be carried out under basic conditions to selectively cleave only one methyl group.^[3] The monodemethylation by NaHMDS at 185 °C under microwave irradiation in a sealed vessel gave monomethyl orcinol 5 in an excellent yield of 95% (Scheme 2).[4] Because these conditions generate an overpressure of ~10 bar when using a half filled vessel, scaling of this reaction was achieved by running multiple batches, which were combined before workup with no effect on yield (~5 g scale). For even larger scales the original procedure which employs NaSEt in DMF to give the product in 80-88% yield might be preferable.^[3b] For the synthesis of the prenylated monomethyl orcinols 6b-c a divergent approach was used. Tsuji Trost allylation^[5] of monomethyl orcinol 5 with tert-

WILEY-VCH

COMMUNICATION

butyl (2-methylbut-3-en-2-yl) carbonate^[6] then gave allyl ether **9** in 94% yield, which underwent a Claisen rearrangement^[7] at 185 °C to give a ~2:1 mixture of the prenylated monomethyl orcinols **6b**^[8] and **6c** which can easily be separated by column chromatography.



Scheme 2. Synthesis of prenylated monomethyl orcinols **6b-c**. Reagents and conditions: a) NaHMDS (2.52 equiv.) in THF, 1,3-dimethyl-2-imidazolidinone, 185 °C, 12 h; b) *tert*-butyl (2-methylbut-3-en-2-yl) carbonate (3.50 equiv.), Pd(PPh₃)₄ (1.00 mol%), 4 Å Molecular sieves, THF, 4 °C, 16 h; c) DMF, 185 °C, microwave irradiation, 1 h.

To synthesize the final isomer **6a** by a cross-coupling approach, bromide **10** was required. Because the literature-known procedure for this compound was a lengthy four step synthesis starting from orcinol yielding the desired compound **10** in 56%

yield^[9], a direct bromination of monomethyl orcinol was investigated. The best results were achieved by a slightly modified procedure of Park *et al.*^[10] using LiBr as bromine source and $(nBu_4N)_2S_2O_8$ as oxidant to give 4-bromo-3-methoxy-5methylphenol **10** as major product in 45% yield (Scheme 3). The isomer 2-bromo-5-methoxy-3-methylphenol (not shown) was isolated as major side product in 23% yield (see supporting information). Attempts to achieve full conversion by increasing the equivalents of LiBr and $(nBu_4N)_2S_2O_8$ or higher temperatures resulted in polybrominated products.



Scheme 3. Synthesis of prenylated monomethyl orcinol 6a. Reagents and conditions: a) LiBr (2.00 equiv.), $(nBu_4N)_2S_2O_8$ (2.00 equiv.), MeCN,0 °C \rightarrow r.t., 16 h; b) prenylzinc bromide (2.33 equiv.) in THF, Xphos Pd G3 (2.00 mol%), XPhos (2.00 mol%), THF, r.t., 16 h. XPhos: 2-Dicyclohexylphosphino-2',4',6'-triisopropylbiphenyl

To achieve prenylation a Negishi coupling approach was employed.^[11] Although, the original report recommends the use of Cphos over Xphos to prevent the formation of reverse prenylated products, Xphos was used as ligand to selectively give the prenylated monomethylorcinol **6a** in an excellent yield of 97%. Isomeric products have not been observed.



Table 1. Optimisation of the diaryl ether coupling. 1.2 equiv. of bromide 11 were used.

Entry	substrate	precatalyst (mol%)	Ligand (mol%)	Base (equiv.)	solvent	T/°C	t	product (yield) ^{a)}
1 ^[]	6a	Cul (10)		Cs ₂ CO ₃ (2.0)	NMP	195 µ~	2 h	- (decomposition)
2[]	6a	Cul (1.0) + Fe(acac)₃ (2.0)		K ₂ CO ₃ (2.0)	DMF	135	16 h	- (no conversion)
3[]	6a	Cu(PPh ₃) ₃ Br	-	Cs ₂ CO ₃ (3.0)	NMP	100	24 h	- (no conversion)
40	6a	Pd(OAc) ₂ (2.0)	tBuXphos (3.0)	K ₃ PO ₄ (2.0)	toluene	100	16 h	- (no conversion)
5	6a	Pd ₂ (dba) ₃ (4.0)	tBuXphos (16)	K ₃ PO ₄ (3.0)	dioxane/water 1:1	100	20 h	7a (16%)
6	6a	Pd ₂ (dba) ₃ (4.0)	tBuXphos (16)	K ₃ PO ₄ (3.0)	dioxane	100	20 h	7a (traces)
7	6a	Pd ₂ (dba) ₃ (4.0)	tBuXphos (16)	K ₃ PO ₄ ·H ₂ O (3.0)	dioxane	100	20 h	7a (88%)
8	6a	Pd ₂ (dba) ₃ (2.0)	<i>t</i> BuXphos (8.0)	K ₃ PO ₄ ·H ₂ O (3.0)	dioxane	100	20 h	7a (67%)
9	6b	Pd ₂ (dba) ₃ (4.0)	tBuXphos (16)	K ₃ PO ₄ ·H ₂ O (3.0)	dioxane	100	20 h	7b (84%)
10	6c	Pd ₂ (dba) ₃ (4.0)	tBuXphos (16)	K ₃ PO ₄ ·H ₂ O (3.0)	dioxane	100	20 h	7c (80%)

The diaryl ether coupling using several Cu and Pd based procedures failed to yield the desired product as they either led to decomposition or no conversion at all.^[12] Reaction conditions which were originally reported to dimerize aryl bromides into aryl ethers gave the desired diaryl ether **7a** in low yield (entry 5).^[13]

GC-MS revealed the presence of the monomethyl orcinol **5**. Since this product can only be formed in the presence of water as OH source, the reaction was attempted without water. This resulted in barely any conversion of the starting bromide, revealing that a certain amount of water was required for the aryl ether coupling

WILEY-VCH

COMMUNICATION

to occur. Employing $K_3PO_4 \cdot H_2O$ as base finally gave the product 7a in a yield of 88%.^[14] The regioisomers have been also synthesized using the same conditions as before giving equally satisfying results when applied to the prenylated monomethylorcinols 6b and 6c to yield 7b (84%) and 7c (80%). The dimethylated diaryl ethers 7a-c were successfully deprotected in excellent yields by in situ generated NaSEt to yield "Verticilatin" 2a (95%), diorcinol D 2b (quant.) and diorcinol I 2c (91%). BBr₃, TMSI and NaHMDS were also tested as deprotecting agents, but all led to decomposition of the starting material.[15]



Scheme 4. Deprotection of methylated diorcinols 7a-c.

The NMR data of synthesized diorcinol D^[1b] **2b** and I^[1c] **2c** in DMSO-*d*₆ both matched the reported data for these compounds. In contrast, the data for diaryl ether **2a** was not in agreement with the NMR data for "Verticilatin"^[1a], which was measured in MeOD. However, the NMR-data of diorcinol D **2b** in MeOD matched the reported data for "Verticilatin" which implies that these two compounds actually have the same structure. This also means that compound **2a** has not been isolated from natural sources so far.



Figure 2. Single crystal X-ray crystal structures of diorcinol D 2b (left) and diorcinol I 2c (right). $^{\rm [16]}$

The chemical structures of diorcinol D **2b** and diorcinol I **2c** were unambiguously confirmed by single crystal X-ray crystallography (figure 2), which confirm the correct assignment of our NMR data.

We also attempted to synthesize compound **3a**, because of reported biological activity against MRSA. The compound **3a** and its analogues **3b-c** were synthesized from **7a-c**.





Scheme 5. Endgame in the synthesis of **3a-c**. Reagents and conditions: a) *m*CPBA (1.50 equiv.), DCM, r.t., 1 h then camphorsulfonic acid (1.15 equiv.), *n*Bu₄NBr (5.00 mol%), water, r.t., 2 h; b) Dess-Martin periodinane (1.50 equiv.), r.t., 2 h.

Epoxidation of the prenyl unit followed by rearrangement of the epoxide led to the allyl alcohols **12a-c** in sufficient yield ranging from 51-56% (Scheme 5).^[17] Subsequent Dess-Martin oxidation gave the compounds **3a-c** in good yields ranging from 89-92%.^[18] Yet again, the data of the presumed natural product, diaryl ether **3a**, did not match the reported data. However, this time it was not possible to identify the actual structure of the reported antibiological compound as the synthetic isomers **3b** and **3c** also did not match the reported data. Thus, further research is required to determine the actual structure of the reported antibiological compound.

In addition, demethylation of **12b** gave *rac*-diorcinol J **4** with matching NMR data (Scheme 6).



Scheme 6. Deprotection of methylated diorcinol J 4.

The antibacterial properties of diorcinols **2a-c**, *rac-***4** and the compounds **3a-c** against Gram-positive bacteria (*Staphylococcus aureus* ATCC25923, MRSA GK2235, MRSA USA300 and *Enteroccocus faecalis* ATCC29212) as well as Gram-negative bacteria (*Pseudomonas aeruginosa* ATCC27853 and *Escherichia coli* ATCC25922), were evaluated by disc diffusion^[19] and minimal inhibitory concentration (MIC) broth dilution assays.^[20] However, diorcinols **2a-c** were able to reduce the biofilm of the Gram-negative bacterium *Stenotrophomonas maltophilia* K279a up to 54% (supporting information).^[21]

In contrast to earlier reports^[1d], compounds **3a-c** showed no antibacterial effects in our assays employing both Methicillinsensitive (MSSA) and -resistant (MRSA) *isolates*. *rac*-**4** also only showed minuscule inhibition of *E. faecalis* and *S. aureus* in the disc diffusion assays.

COMMUNICATION

Table 2.: MIC in mg/L of compounds 2a-c, *rac-*4 and 3a-c against Gram-positive MSSA and MRSA clinical isolates. Tetracycline and vancomycin were used as references.

O a man a sum al	MSSA	MRSA	MRSA	E. faecalis
Compound	ATCC25923	GK2235	USA300	ATCC29212
Tetracycline	1	64	1	16
Vancomycin	2	2	1	4
2a	4	4	4	4
Diorcinol D 2b	8	8	4	8
Diorcinol I 2c	8	8	8	8
Diorcinol J 4	>64	>64	>64	>64
3a	-	-	-	-
3b	-	-	-	-
3c	-	-	-	-

While the diorcinols **2a-c** did not show growth inhibition of the Gram-negative bacteria, they exhibited antibacterial properties against the Gram-positive bacterial strains *E. faecalis* and *S. aureus* at concentrations of 4-8 mg/L, regardless of methicillin resistance (Table 2). Out of all compounds, the so far non-natural diaryl ether **2a** performed the best in terms of antibiotic activity.

We herein report the first syntheses of the natural products diorcinol D 2b, I 2c and J 4 in only five linear steps with satisfying overall yields (51% (2b), 20% (2c), 16% (4)). Furthermore, structure 2a, which originally was assigned to Verticilatin, and an the structure 3a which was assigned to an antibiotic compound by Li et al. have been synthesized in overall yields of 35% (2c) and 17% (3a). The synthesis revealed that Verticilatin, which was originally assigned to structure 2a is actually diorcinol D 2b. In addition, the actual structure of the antibiotic compound 3a reported by Li et al. could not be confirmed by our total synthetic approach. The analogues 3b and 3c, which have been synthesized in six linear steps and overall yields of 26% (3a) and 10% (3c), also did not match with the reported data for the natural product. Of all the synthesized compounds, only diorcinol D 2b, I 2c and their synthetic isomer 2a showed significant inhibition of both methicillin sensitive (MSSA) and resistant (MRSA) strains of S. aureus as well as E. faecalis. Overall, this short synthetic approach towards the diorcinols showed to be useful, not only for biological, but also structural evaluation of this compound class.

Acknowledgements

We thank the Fonds der Chemischen Industrie (FCI) for generous financial support. G.J.B. thanks the Universität Hamburg for a PhD fellowship (Hamburg Stipendium). W.R.S and M.G. thank the Rahn-Quade foundation for funding. Furthermore, we thank I. Nevoigt for technical support.

Keywords: MRSA • Total Synthesis • Natural Products • Biofilm • Structure Elucidation

WILEY-VCH

VIANUSC

- a) P. W. Wie, L. Li, C.-G. Yang, D.-Q. Luo, Z.-H. Zheng, X.-H. Lu, B.-Z. [1] Shi, J. Asian Nat. Prod. Res. 2014, 16, 1153–1157; b) H. Gao, L. Zhou, S. Cai, G. Zhang, T. Zhu, Q. Gu, D. Li, J. Antibiot. 2013, 66, 539-542; c) X.-B. Li, Y.-H. Zhou, R.-X. Zhu, W.-Q. Chang, H.-Q. Yuan, W. Hao, L.-L. Zhang, Z.-T. Zhao, H.-X. Lou, Chem. Biodivers. 2015, 12, 575-592; d) Z.-J. Li, H.-Y.-Yang, J. Li, X. Liu, L. Ye, W.S. Kong, S.-Y. Tang, G. Du, Z.-H. Liu, M. Zhou, G.-Y. Yang, Q.-F. Hu, X.-M. Li, J. Antibiot. 2018 71, 359-362; e) S.-W. Yang, T.-M. Chan, R. Patel, J. Terracciano, D. Loebenberg, M. Patel, M. Chu J.-H. Jang, K. Kanoh, K. Adachi, Y. Shizuri, J. Antibiot. 2006, 59, 428–431; f) O. I. Zhuravleva, N. N. Kirichuck, V. A. Denisenko, P. S. Dimitrenok, E. A. Yurchenko, E. M. Minko, E. V. Ivanets, S. S. Afiyatullov, Chem. Nat. Compd.. 2016, 52, 227-230; g) O. I. Zhuravleva, S. Sh. Afiyatullov, E. A. Yurchenko, V. A. Denisenko, N. N. Kirichuck, P. S. Dmitrenok, Nat. Prod. Comm. 2013, 8, 1071-1074; h) X. Wang, Y. Mou, J. Hu, N. Wang, L. Zhao, L. Liu, S. Wang, D. Meng, Chem. Biodivers. 2014, 11, 133–139; i) Sh.-Sh. Hu, N. Jiang, X.-L. Wang, C.-J. Chen, J.-Y. Fan, G. Wurin, H.-M. Ge, R.-X. Tan, R.-H. Jiao, Tetrahedron Lett. 2015, 56, 3894–3897; j) X. Xu, H. Yang, H. Xu, L. Yin, Z. Chen, H. Shen, Nat. Prod. Res. 2018, 32, 821-825; k) Z.-X. Li, X.-F. Wang, G.-W. Ren, X.-L. Yuan, N. Deng, G.X. Ji, W. Li, P. Zhang, Molecules 2018, 23, 2368-2375; I) P. Zhang, X. Li, X.-L- Yuan, Y.-M. Du, B.-G. Wang, Z.-F. Zhang, Molecules 2018, 23, 3179-3186.
- a) K. Hotta, X. Chen, R. S. Paton, A. Minami, H. Li, K. Swaminathan, I. I.
 Mathews, K. Watanabe, H. Oikawa, K. N. Houk, C.-Y. Kim, *Nature* 2012, 483, 355–358; b) B.-B. He, T. Zhou, X.-L. Bu, J.-Y. Weng, J. Xu, S. Lin, J.-T. Zheng, Y.-L.Zhao, M.-J. Xu, *ACS Catal.* 2019, *9*, 6, 5391-5399.
- a) G. I. Feutrill and R. N. Mirrington, *Aust. J. Chem.* **1972**, 1719; b) R. N.
 Mirrington, G. I. Feutrill, H. Gurien, G. Kaplan, A. Brossi, *Org. Synth.* **1973**, 53, 90.
- [4] J. R. Hwu, F. F. Wong, J.-J. Huang, S.-C. Tsay, J. Org. Chem. 1997, 62, 12, 4097–4104.
- [5] B. M. Trost, Pure Appl. Chem. 1981, 53, 2357, J. Tsuji, Pure Appl. Chem. 1982, 54, 197.
- [6] R. Matunas A. J. Lai, C. Lee, Tetrahedron, 2005, 91, 26, 6298–6308.
- [7] L. Claisen, Ber. Dtsch. Chem. Ges. 1912, 45, 3157–3166.
- [8] W. Shao, D. L. J. Clive, J. Org. Chem. 2015, 80, 3211–3216.
- [9] T. Hattori, Y. Shimazumi, H. Goto, O. Yamabe, N. Morohashi, W. Kawai,
 S. Miyano, J. Org. Chem. 2003, 68, 2099–2108.
- [10] M. Y. Park, S. G. Yang, V. Jadhav, Y. H. Kim, *Tet. Lett.* 2004, 45, 25, 4887–4890.
- A. O. King, N. Okukado, E.-i. Negishi, *Chem. Comm.* **1977**, 683; Y. Yang,
 T. J. L. Mustard, P. H.-Y Cheong, S. L. Buchwald, *Angew.Chem.Int. Ed.* **2013**, *52*, 14098–14102; A.Krasovskiy, P. Knochel, *Synthesis* **2006**, 890–891.
- R. Gujadhur, D. Venkataraman H. Synth. Commun, 2001, 31, 18, 2865–2879; He, Y.-J. Wu, *Tet. Lett.* 2003, 44, 17, 3445–3446; C. H. Burgos, T. E. Barder, X. Huang, S. L. Buchwald, *Angew. Chem. Int. Ed.* 2006, 45, 4321–4326; Y. Liu, S. Zhang, *Synlett*, 2011, 2, 268–272.
- [13] K. W. Anderson, T. Ikawa, R. E. Tundel, S. L. Buchwald, J. Am. Chem. Soc. 2006, 128, 33, 10694–10695.
- [14] G. Chen, A. S. C. Chan, F. Y. Kwong, Tet. Lett. 2004, 45, 25, 4887–4890.
- F. L. Benton, T. E. Dillon J. Am. Chem. Soc. 1942, 64, 5, 1128–1129; M.
 E. Jung, M. A. Lyster, J. Org. Chem. 1977, 42, 23, 3761–3764.
- [16] These data are deposited at The Cambridge Crystallographic Data Centre and can be obtained via www.ccdc.cam.ac.uk/data_request/cif diorcinol D 2b: (CCDC 2003759) diorcinol I 2c: (CCDC 2003758)
- [17] L. F. Tietze, T. Eicher, U. Diederichsen, A. Speicher, N. Schützenmeister in *Reactions and Syntheses : In the Organic Chemistry Laboratory* Wiley-VCH, Weinheim, **2015**, pp. 456; T. Kimachi, E. Torii, Y. Kobayashi, M. Doe, M. Ju-Ichi, *Chem. Pharm. Bull.* **2011**, *59*, 6, 753–756.
- [18] D. B. Dess, J. C. Martin, J. Org. Chem. 1983, 48, 22, 4155–4156.
- [19] A. W. Bauer, W.M.M. Kirby, J.C. Sherris, M. Turc, Am. J. Clin. Pathol. 1966, 45, 493–496.
- [20] J. M. Andrews, J. Antimicrob. Chemot. 2001, 48, 5–16.
- [21] J. Steinmann, U. Mamat, E. M. Abda, L. Kirchhoff, W. R. Streit, U. E. Schaible, S. Niemann, T. A. Kohl, *Front. Microbiol.* **2018**, *9*, Article 806. doi: 10.3389/fmicb.2018.00806

WILEY-VCH

COMMUNICATION

Entry for the Table of Contents



Family reunion – the 7 kids of Dimethylorcinol. A short and divergent total synthetic approach towards diorcinols and related structures yielded seven different diaryl ether employing a Pd-catalyzed diaryl ether coupling as key step. Three members of the natural product class family exhibit anti-MRSA and biofilm activity.

Institute and/or researcher Twitter usernames: Schuetzenmeist1